Drug Profile
Research programme: orexin 1 receptor antagonist - AstraZeneca/Eolas
Latest Information Update: 28 Aug 2019
Price :
$50
*
At a glance
- Originator Eolas Therapeutics
- Developer AstraZeneca
- Class Drug withdrawal therapies
- Mechanism of Action Orexin receptor type 1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neurological disorders; Substance-related disorders
Most Recent Events
- 28 Aug 2019 No recent reports of development identified for preclinical development in Neurological-disorders in USA
- 28 Aug 2019 No recent reports of development identified for preclinical development in Substance-related disorders in USA
- 30 Jun 2015 Eolas orexin-1 receptor antagonist licensed to AstraZeneca worldwide